Uroplasty Company Profile (NYSE:UPI)

About Uroplasty (NYSE:UPI)

Uroplasty logoCogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Devices & Implants
  • Sub-Industry: N/A
  • Symbol: NYSE:UPI
  • CUSIP: N/A
  • Web: www.uroplasty.com/
Average Prices:
  • 50 Day Moving Avg: $1.00
  • 200 Day Moving Avg: $1.00
  • 52 Week Range: $1.00 - $4.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: Infinity
  • P/E Growth: 0
Profitability:
  • Net Margins: -31.58%
  • Return on Equity: -87.33%
  • Return on Assets: -60.82%
Misc:
  • Average Volume: 204,569 shs.
 
Frequently Asked Questions for Uroplasty (NYSE:UPI)

What is Uroplasty's stock symbol?

Uroplasty trades on the New York Stock Exchange (NYSE) under the ticker symbol "UPI."

How were Uroplasty's earnings last quarter?

Uroplasty, Inc. (NYSE:UPI) posted its earnings results on Thursday, January, 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The firm had revenue of $6.67 million for the quarter, compared to analyst estimates of $6.89 million. Uroplasty had a negative return on equity of 87.33% and a negative net margin of 31.58%. View Uroplasty's Earnings History.

Who are some of Uroplasty's key competitors?

How do I buy Uroplasty stock?

Shares of Uroplasty can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Uroplasty's stock price today?

One share of Uroplasty stock can currently be purchased for approximately $1.00.


MarketBeat Community Rating for Uroplasty (NYSE UPI)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Uroplasty (NYSE:UPI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Uroplasty (NYSE:UPI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Uroplasty (NYSE:UPI)
Earnings by Quarter for Uroplasty (NYSE:UPI)
Earnings History by Quarter for Uroplasty (NYSE UPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/22/2015Q3($0.04)($0.06)$6.89 million$6.67 millionViewListenView Earnings Details
10/23/2014Q2($0.07)($0.05)$6.49 million$6.46 millionViewListenView Earnings Details
7/24/2014Q1($0.05)($0.10)$6.35 million$6.39 millionViewListenView Earnings Details
5/15/2014Q4 13($0.04)($0.05)$6.40 million$6.36 millionViewN/AView Earnings Details
1/23/2014Q314($0.04)($0.03)$6.13 million$6.40 millionViewListenView Earnings Details
10/24/2013Q214($0.05)($0.04)$6.09 million$6.00 millionViewListenView Earnings Details
5/30/2013Q4 2013($0.04)($0.05)$5.59 million$5.54 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Uroplasty (NYSE:UPI)
Current Year EPS Consensus Estimate: $-0 EPS

Dividends

Dividend History for Uroplasty (NYSE:UPI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Uroplasty (NYSE:UPI)
Insider Trades by Quarter for Uroplasty (NYSE:UPI)
Insider Trades by Quarter for Uroplasty (NYSE:UPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/30/2015Brett ReynoldsCFOBuy5,000$1.32$6,600.00View SEC Filing  
1/29/2015Kevin H RocheDirectorBuy50,000$1.23$61,500.00View SEC Filing  
1/29/2015Robert KillCEOBuy25,000$1.26$31,500.00View SEC Filing  
7/30/2014Kevin H RocheDirectorBuy10,000$2.45$24,500.00View SEC Filing  
7/29/2014Kevin H RocheDirectorBuy9,000$2.44$21,960.00View SEC Filing  
6/3/2014Kevin H RocheDirectorBuy10,000$2.97$29,700.00View SEC Filing  
6/2/2014Robert KillCEOBuy13,950$2.95$41,152.50View SEC Filing  
3/6/2014Susan Hartjes HolmanVPSell38,000$3.98$151,240.00View SEC Filing  
1/29/2014Susan Hartjes HolmanSVPSell52,500$4.59$240,975.00View SEC Filing  
12/11/2013Robert Patrick MaxwellDirectorSell3,819$2.70$10,311.30View SEC Filing  
8/23/2013Brett ReynoldsCFOBuy8,000$2.99$23,920.00View SEC Filing  
8/23/2013James StaunerDirectorBuy8,300$3.03$25,149.00View SEC Filing  
8/7/2013Robert KillCEOBuy36,050$2.77$99,858.50View SEC Filing  
8/6/2013Darin HammersVPBuy6,800$2.82$19,176.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Uroplasty (NYSE:UPI)
Latest Headlines for Uroplasty (NYSE:UPI)
Source:

Social

Chart

Uroplasty (UPI) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff